Sensus (SRTS) Q2 Revenue Falls 21%
Sensus Healthcare (NASDAQ:SRTS), a medical device maker specializing in non-invasive dermatology treatments, reported its second-quarter earnings on August 7, 2025. The headline news was a substantial miss on both revenue and profitability, with reported GAAP revenue well below Wall Street expectations. Revenue (GAAP) dropped to $7.3 million, notably under the consensus GAAP estimate of $9.3 million and down from $9.2 million (GAAP) in Q2 2024. The firm posted a net loss per share of $0.06 (GAAP), and last year’s $0.10 profit (GAAP, Q2 2024). Gross margin shrank to 39.7%, a sharp year-over-year slide in revenue. Overall, the quarter reflected operational and market headwinds, driving a notable step back in both sales and profitability.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Sensus Healthcare manufactures and sells superficial radiation therapy (SRT) systems, which are medical devices that offer non-invasive treatment for non-melanoma skin cancers and keloids. Its SRT systems present an alternative to surgery by using targeted radiation, typically offered within dermatology practices and, increasingly, by radiation oncologists. The company’s product family also includes the TDI system, designed for transdermal drug infusion, though it remains pre-commercial.
Source Fool.com
